Format
Sort by
Items per page

Send to

Choose Destination

Search Tip

Sort by Best Match to display results from highest to lowest relevance to your search terms.

Try it Now

Search results

Items: 1 to 20 of 5520

1.

Heterogeneity in tuberculosis.

Cadena AM, Fortune SM, Flynn JL.

Nat Rev Immunol. 2017 Jul 24. doi: 10.1038/nri.2017.69. [Epub ahead of print] Review.

PMID:
28736436
2.

Safety and effectiveness of tocilizumab in treating patients with rheumatoid arthritis - A three-year study in Taiwan.

Lin CT, Huang WN, Hsieh CW, Chen YM, Chen DY, Hsieh TY, Chen YH.

J Microbiol Immunol Infect. 2017 Jul 1. pii: S1684-1182(17)30105-6. doi: 10.1016/j.jmii.2017.04.002. [Epub ahead of print]

3.

Tuberculosis in Children.

Thomas TA.

Pediatr Clin North Am. 2017 Aug;64(4):893-909. doi: 10.1016/j.pcl.2017.03.010. Review.

PMID:
28734517
4.

Proteogenomic analysis and discovery of immune antigens in Mycobacterium vaccae.

Zheng J, Chen L, Liu L, Li H, Liu B, Zheng D, Liu T, Dong J, Sun L, Zhu Y, Yang J, Zhang X, Jin Q.

Mol Cell Proteomics. 2017 Jul 21. pii: mcp.M116.065813. doi: 10.1074/mcp.M116.065813. [Epub ahead of print]

5.

Tuberculosis and biologics in rheumatology: India - A special situation.

Handa R, Upadhyaya S, Kapoor S, Jois R, Pandey BD, Bhatnagar AK, Khanna A, Goyal V, Kumar K.

Int J Rheum Dis. 2017 Jul 21. doi: 10.1111/1756-185X.13129. [Epub ahead of print] Review.

PMID:
28730751
6.

Tuberculosis and its particularities in Romania and worldwide.

NiŢu FM, Olteanu M, Streba CT, Jimborean G, Postolache P, Man MA, Trofor AC, Nemeş RM, Dragonu L, Olteanu M.

Rom J Morphol Embryol. 2017;58(2):385-392.

7.

Exposure to the Epstein-Barr Viral Antigen Latent Membrane Protein 1 Induces Myelin-Reactive Antibodies <i>In Vivo</i>.

Lomakin Y, Arapidi GP, Chernov A, Ziganshin R, Tcyganov E, Lyadova I, Butenko IO, Osetrova M, Ponomarenko N, Telegin G, Govorun VM, Gabibov A, Belogurov A Jr.

Front Immunol. 2017 Jul 6;8:777. doi: 10.3389/fimmu.2017.00777. eCollection 2017.

8.

[Tuberculosis treatment for children: An update].

Mellado Peña MJ, Santiago García B, Baquero-Artigao F, Moreno Pérez D, Piñeiro Pérez R, Méndez Echevarría A, Ramos Amador JT, Gómez-Pastrana Durán D, Noguera Julian A; Grupo de Trabajo de Tuberculosis e Infección por otras Micobacterias de la Sociedad Española de Infectología Pediátrica.

An Pediatr (Barc). 2017 Jul 17. pii: S1695-4033(17)30225-4. doi: 10.1016/j.anpedi.2017.05.013. [Epub ahead of print] Spanish.

9.

Suggestions for Promoting Evidence-based Public Health in Korea.

Bae JM.

Epidemiol Health. 2017 Jul 19. doi: 10.4178/epih.e2017030. [Epub ahead of print]

10.

Cost-Effectiveness of isoniazid preventive therapy among HIV-infected patients clinicaly screened for latent tuberculosis infection in Dar es Salaam, Tanzania: A prospective Cohort study.

Shayo GA, Chitama D, Moshiro C, Aboud S, Bakari M, Mugusi F.

BMC Public Health. 2017 Jul 19;18(1):35. doi: 10.1186/s12889-017-4597-9.

11.

Predicting susceptibility to tuberculosis based on gene expression profiling in dendritic cells.

Blischak JD, Tailleux L, Myrthil M, Charlois C, Bergot E, Dinh A, Morizot G, Chény O, Platen CV, Herrmann JL, Brosch R, Barreiro LB, Gilad Y.

Sci Rep. 2017 Jul 18;7(1):5702. doi: 10.1038/s41598-017-05878-w.

12.

Factors That Influence Treatment Completion for Latent Tuberculosis Infection.

Eastment MC, McClintock AH, McKinney CM, Narita M, Molnar A.

J Am Board Fam Med. 2017 Jul-Aug;30(4):520-527. doi: 10.3122/jabfm.2017.04.170070.

13.

In This Issue: Opiates, Tobacco, Social Determinants of Health, Social Accountability for Non-Profit Hospitals, More on PCMH, and Clinical Topics.

Bowman MA, Victoria Neale A, Seehusen DA.

J Am Board Fam Med. 2017 Jul-Aug;30(4):399-401. doi: 10.3122/jabfm.2017.04.170192.

14.

Prevalence and risk factors of latent tuberculosis infection in Africa: a systematic review and meta-analysis protocol.

Basera TJ, Ncayiyana J, Engel ME.

BMJ Open. 2017 Jul 18;7(7):e012636. doi: 10.1136/bmjopen-2016-012636.

15.

Incidence of active tuberculosis in individuals with latent tuberculosis infection in rural China: follow-up results of a population-based, multicentre, prospective cohort study.

Gao L, Li X, Liu J, Wang X, Lu W, Bai L, Xin H, Zhang H, Li H, Zhang Z, Ma Y, Li M, Feng B, Du J, Sui H, Zhao R, Su H, Pan S, Guan L, Shen F, He J, Yang S, Si H, Cheng X, Xu Z, Tan Y, Chen T, Xu W, Peng H, Wang Z, Zhu T, Chen X, Zhou X, Guan X, Jin Q; LATENTTB-NSTM study team.

Lancet Infect Dis. 2017 Jul 14. pii: S1473-3099(17)30402-4. doi: 10.1016/S1473-3099(17)30402-4. [Epub ahead of print]

PMID:
28716677
16.

Latent tuberculosis infection in rural China: who will develop tuberculosis?

Zellweger JP.

Lancet Infect Dis. 2017 Jul 14. pii: S1473-3099(17)30441-3. doi: 10.1016/S1473-3099(17)30441-3. [Epub ahead of print] No abstract available.

PMID:
28716676
17.

Testing the External Validity of a Discrete Choice Experiment Method: An Application to Latent Tuberculosis Infection Treatment.

Mohammadi T, Bansback N, Marra F, Khakban A, Campbell JR, FitzGerald JM, Lynd LD, Marra CA.

Value Health. 2017 Jul - Aug;20(7):969-975. doi: 10.1016/j.jval.2017.04.007. Epub 2017 May 19.

PMID:
28712627
18.

Striking the right immunological balance prevents progression of tuberculosis.

Vyas SP, Goswami R.

Inflamm Res. 2017 Jul 15. doi: 10.1007/s00011-017-1081-z. [Epub ahead of print] Review.

PMID:
28711989
19.

A Multistage Subunit Vaccine Effectively Protects Mice Against Primary Progressive Tuberculosis, Latency and Reactivation.

Ma J, Teng X, Wang X, Fan X, Wu Y, Tian M, Zhou Z, Li L.

EBioMedicine. 2017 Jul 8. pii: S2352-3964(17)30268-2. doi: 10.1016/j.ebiom.2017.07.005. [Epub ahead of print]

20.

Breaking Transmission with Vaccines: The Case of Tuberculosis.

Gonzalo-Asensio J, Aguilo N, Marinova D, Martin C.

Microbiol Spectr. 2017 Jul;5(4). doi: 10.1128/microbiolspec.MTBP-0001-2016.

PMID:
28710848

Supplemental Content

Loading ...
Support Center